Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Influence of food on serum ambenonium concentration in patients with myasthenia gravis

  • 29 Accesses


Influence of food on the serum concentration and kinetics ambenonium chloride (AMBC) has been examined in thirteen patients with myasthenia gravis (MG).

Mean serum concentrations and Cmax during fasting were higher than those in the non-fasting state. The AUC (0–3 h) was also about four-times larger.

The drug effects versus the serum concentration were observed to be anti-clockwise or clockwise. The effective range of the Cmax varied between patients. The unexpected increase in Cmax led to adverse muscarinic actions of AMBC, when the condition was changed from the non-fasting to the fasting state.

It is recommended that the dose be changed during non-fasting treatment when adjusting the optimum regimen for patients myasthenia gravis. Patients must be advised to keep to the dosing and dietary schedule in order to avoid unexpected adverse actions to AMBC.

This is a preview of subscription content, log in to check access.


  1. 1.

    Ohtsubo K, Higuchi S, Aoyama T, Fujii N, Goto I (1989) Sensitive determination of ambenonium chloride in serum from patients with myasthenia gravis using ion-exchange resin extraction and reversed-phase ion-pair chromatography. J Chromatogr 496: 397–406

  2. 2.

    Yamaoka K, Nakagawa T, Uno T (1978) Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 6: 547–558

  3. 3.

    Aquilonius SM, Eckenrnas SA, Hartvig P, Lindstrom B, Osterman PO (1980) Pharmacokinetics and oral bioavailability of pyridostigmine in man. Eur J Pharmacol 18: 423–428

  4. 4.

    Sorensen PS, Flachs H, Friis ML, Hvidberg EF, Paulson O (1984) Steady state kinetics of pyridostigmine in myasthenia gravis. Neurology 34: 1020–1024

  5. 5.

    Breyer-Pfaff U, Maier U, Brinkmann AM, Schumm F (1985) Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis. Clin Pharmacol Ther 37: 495–501

  6. 6.

    Levine RR, Blair MR, Clark BB (1955) Factors influencing the intestinal absorption of certain monoquaternary anticholinergic compounds with special reference to benzomethamin [N-diethylaminoethyl-N′-methyl-benzilamide methobromide]. J Pharmacol Exp Ther 114: 78–86

  7. 7.

    Levine RR (1966) Mechanism of intestinal absorption, as they relate to quaternary ammonium compounds. Arzneimittel-Forsch 16: 1373–1375

  8. 8.

    Saitoh H, Hasegawa N, Kawai S, Miyazaki K, Arita T (1986) Interaction of tertiary amines and quaternary ammonium compounds with gastrointestinal mucin. J Pharmacobio-Dyn 9: 1008–1014

  9. 9.

    Saitoh H, Kawai S, Miyazaki K, Arita T (1988) Transport characteristics of propantheline across rat intestinal brush border membrane. J Pharm Pharmacol 40: 176–180

  10. 10.

    Chan K, Calvey TN (1987) Plasma concentration of pyridostigmine and effecsin myasthenia gravis. Clin Pharmacol Ther 22: 596–601

  11. 11.

    Davison SC, Hyman NM, Dehghan A, Chan K (1981) The relationship of plasma levels of pyridostigmine to clinical effect in patients with myasthenia gravis. J Neurol Neurosurg Psychiatry 44: 1141–1145

  12. 12.

    Aquilonius SM, Eckernas SA, Hartvig P, Lindstrom B, Osterman P, Stalberg E (1983) Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis. J Neurol Neurosurg Psychiatry 46: 929–935

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ohtsubo, K., Fujii, N., Higuchi, S. et al. Influence of food on serum ambenonium concentration in patients with myasthenia gravis. Eur J Clin Pharmacol 42, 371–374 (1992).

Download citation

Key words

  • Ambenonium chloride
  • Myasthenia gravis
  • dietary effect
  • serum concentration
  • adverse effects
  • pharmacokinetics